Laurus Labs Reports Negative Financial Performance in Q4 2023, Stock Rated as 'Hold' by MarketsMOJO

Laurus Labs, a largecap pharmaceutical company, recently announced its financial results for the quarter ending December 2023. The company's stock call has been rated as 'Hold' by MarketsMOJO.

According to the financial report, Laurus Labs has seen a very negative performance in the quarter, with a score of -26 compared to -19 in the previous quarter. This decline can be attributed to various factors, including a decrease in net sales, profit before tax, and profit after tax.

The net sales for the quarter were reported at Rs 1,194.92 crore, showing a significant decline of -22.65% year on year. This trend is expected to continue in the near term. Similarly, the profit before tax less other income (PBT) has also fallen by -88.35% year on year, with a near term trend that is also very negative. The same can be said for the profit after tax (PAT), which has fallen by -88.6% year on year.

One concerning aspect of the financial report is the company's operating profit to interest ratio, which is at its lowest in the last five quarters at 3.57 times. This indicates a deteriorating ability to manage interest payments. Additionally, the PBT has also hit its lowest point in the last five quarters at Rs 32.19 crore, with a negative trend in the near term. The earnings per share (EPS) have also declined, reaching its lowest point at Rs 0.43 in the last five quarters. This shows a decline in profitability and lower earnings for shareholders.

Overall, Laurus Labs has reported a negative financial performance in the quarter ending December 2023. Investors are advised to hold their stock and monitor the company's future performance closely.